BASF Receives EXCiPACT Certification - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

BASF Receives EXCiPACT Certification

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 2

BASF has received the EXCiPACT Certificate for pharmaceutical excipients for the group of polyvinylpyrrolidone (Kollidon) polymers, produced in Ludwigshafen, Germany. The certificate was issued by mdc medical device certification GmbH, one of EXCiPACT’s internationally-recognized certification bodies. The certification demonstrates that BASF manufacturers and distributes pharmaceutical excipients according to the EXCiPACT GMP.

The EXCiPACT scheme can be made available when the regulators in the EU and USA require the holder of the marketing authorization for medicines to ensure that appropriate GMP and GDP is applied to the manufacture and distribution of both APIs and excipients, BASF reports. The US Food and Drug Administration and the European Medicines Agency require drug producers to qualify excipient suppliers and suppliers must be prepared to receive increasing numbers of audits from their customers. EXCiPACT helps to avoid additional audits in a cost-effective manner for all parties concerned because one single audit will be all it takes to prove an excipient complies with current GMP and GDP requirements, according to a BASF statement.

BASF is the third company that has been certified by EXCiPACT according to the EXCiPACT Association’s Global Steering Committee. BASF will conduct recertification audits every three years, plus annual surveillance audits to ensure the continued safety and quality of excipients.

Source: BASF


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here